首页> 外文期刊>Journal of pediatric hematology/oncology: Official journal of the American Society of Pediatric Hematology/Oncology >Rapid Acquisition of Immunologic Tolerance to Factor VIII and Disappearance of Anti-factor VIII IgG4 After Prophylactic Therapy in a Hemophilia A Patient With High-titer Factor VIII Inhibitor
【24h】

Rapid Acquisition of Immunologic Tolerance to Factor VIII and Disappearance of Anti-factor VIII IgG4 After Prophylactic Therapy in a Hemophilia A Patient With High-titer Factor VIII Inhibitor

机译:血友病的预防性治疗后快速获得对因子VIII的免疫耐受和抗因子VIII IgG4的消失高血型因子VIII抑制剂的患者

获取原文
获取原文并翻译 | 示例
           

摘要

We report an 11-month-old boy with severe hemophilia A who had regular exposure to factor VIII (FVIII) intended to reduce the risk of developing an inhibitor. He developed a high-titer inhibitor (peak titer 19 BU) that disappeared within 6 weeks of starting immune tolerance induction (ITI). Anti-FVIII IgG4 peaked briefly compared with anti-FVIII IgG1 and the Bethesda titer. Neither rapid resolution of an inhibitor after prophylaxis nor this behavior of anti-FVIII IgG4 has been previously reported. Transient anti-FVIII IgG4 may be a marker of an attenuated anti-FVIII response induced by prophylactic FVIII therapy.
机译:我们报告了一个11个月大的重度A型血友病男孩,他定期暴露于VIII因子(FVIII)中,目的是降低开发抑制剂的风险。他开发了一种高滴度抑制剂(峰值滴度19 BU),在开始免疫耐受诱导(ITI)后的6周内消失了。与抗FVIII IgG1和贝塞斯达效价相比,抗FVIII IgG4短暂达到峰值。既没有报道预防后抑制剂的快速拆分,也没有报道抗FVIII IgG4的这种行为。瞬时性抗FVIII IgG4可能是预防性FVIII治疗诱导的抗FVIII减毒反应的标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号